Literature DB >> 19762338

Stability in community-acquired pneumonia: one step forward with markers?

R Menéndez1, R Martinez, S Reyes, J Mensa, E Polverino, X Filella, C Esquinas, A Martinez, P Ramirez, A Torres.   

Abstract

BACKGROUND: Biological markers as an expression of systemic inflammation have been recognised as useful for evaluating the host response in community-acquired pneumonia (CAP). The objective of this study was to evaluate whether the biological markers procalcitonin (PCT) and C-reactive protein (CRP) might reflect stability after 72 h of treatment and the absence of subsequent severe complications.
METHODS: A prospective cohort study was performed in 394 hospitalised patients with CAP. Clinical stability was evaluated using modified Halm's criteria: temperature <or=37.2 degrees C; heart rate <or=100 beats/min; respiratory rate <or=24 breaths/min; systolic blood pressure >or=90 mm Hg; oxygen saturation >or=90%; or arterial oxygen tension >or=60 mm Hg. PCT and CRP levels were measured on day 1 and after 72 h. Severe complications were defined as mechanical ventilation, shock and/or intensive care unit (ICU) admission, or death after 72 h of treatment.
RESULTS: 220 patients achieved clinical stability at 72 h and had significantly lower levels of CRP (4.2 vs 7 mg/dl) and of PCT (0.33 vs 0.48 ng/ml). Regression logistic analyses were performed to calculate several areas under the ROC curve (AUC) to predict severe complications. The AUC for clinical stability was 0.77, 0.84 when CRP was added (p = 0.059) and 0.77 when PCT was added (p = 0.45). When clinical stability was achieved within 72 h and marker levels were below the cut-off points (0.25 ng/ml for PCT and 3 mg/dl for CRP), no severe complications occurred.
CONCLUSIONS: Low levels of CRP and PCT at 72 h in addition to clinical criteria might improve the prediction of absence of severe complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762338     DOI: 10.1136/thx.2009.118612

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

Review 1.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

Review 2.  Predictors of treatment failure and clinical stability in patients with community acquired pneumonia.

Authors:  Deirdre Morley; Antoni Torres; Catia Cillóniz; Ignacio Martin-Loeches
Journal:  Ann Transl Med       Date:  2017-11

3.  Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia.

Authors:  A Lacoma; N Rodríguez; C Prat; J Ruiz-Manzano; F Andreo; A Ramírez; A Bas; M Pérez; V Ausina; J Domínguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-26       Impact factor: 3.267

Review 4.  The management of community-acquired pneumonia in the elderly.

Authors:  Paola Faverio; Stefano Aliberti; Giuseppe Bellelli; Giulia Suigo; Sara Lonni; Alberto Pesci; Marcos I Restrepo
Journal:  Eur J Intern Med       Date:  2013-12-17       Impact factor: 4.487

5.  Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.

Authors:  Mona Bafadhel; Tristan W Clark; Carlene Reid; Marie-Jo Medina; Sally Batham; Michael R Barer; Karl G Nicholson; Christopher E Brightling
Journal:  Chest       Date:  2010-10-28       Impact factor: 9.410

6.  The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.

Authors:  Diego Viasus; Carolina Garcia-Vidal; Antonella F Simonetti; Jordi Dorca; Ferran Llopis; Mariona Mestre; Francisco Morandeira-Rego; Jordi Carratalà
Journal:  BMJ Open       Date:  2015-01-06       Impact factor: 2.692

7.  Predictors and Implications of Early Clinical Stability in Patients Hospitalized for Moderately Severe Community-Acquired Pneumonia.

Authors:  Nicolas Garin; Garance Felix; Christian Chuard; Daniel Genné; Sebastian Carballo; Olivier Hugli; Olivier Lamy; Christophe Marti; Mathieu Nendaz; Olivier Rutschmann; Stephan Harbarth; Arnaud Perrier
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

8.  Time-dependent association of glucocorticoids with adverse outcome in community-acquired pneumonia: a 6-year prospective cohort study.

Authors:  Manuela Nickler; Manuel Ottiger; Christian Steuer; Alexander Kutz; Mirjam Christ-Crain; Werner Zimmerli; Robert Thomann; Claus Hoess; Christoph Henzen; Luca Bernasconi; Andreas Huber; Beat Mueller; Philipp Schuetz
Journal:  Crit Care       Date:  2017-03-24       Impact factor: 9.097

Review 9.  Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia.

Authors:  Mi Suk Lee; Jee Youn Oh; Cheol In Kang; Eu Suk Kim; Sunghoon Park; Chin Kook Rhee; Ji Ye Jung; Kyung Wook Jo; Eun Young Heo; Dong Ah Park; Gee Young Suh; Sungmin Kiem
Journal:  Infect Chemother       Date:  2018-06

10.  Coenzyme q10 administration in community-acquired pneumonia in the elderly.

Authors:  Aliasghar Farazi; Masoomeh Sofian; Mansoureh Jabbariasl; Banafshe Nayebzadeh
Journal:  Iran Red Crescent Med J       Date:  2014-12-01       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.